Table 1.

Activating genetic alterations in FGFR and related cancer types

GeneAlterationCancer type (incidence, if known; reference)
FGFR1AmplificationSquamous NSCLC (20%; ref. 9)
Breast cancer (10%; ref. 10)
Ovarian cancer (∼5%; ref. 11)
Bladder cancer (3%; ref. 12)
Others: oral squamous cell carcinoma, esophageal squamous carcinoma, prostate cancer (13–15)
MutationMelanoma (rare), glioblastoma (16, 17)
Translocation8p11 myeloproliferative syndrome, chronic myeloid leukemia (rare; refs. 18, 19)
FGFR2AmplificationGastric cancer (10%; ref. 20)
Breast cancer (4% of triple-negative cases; ref. 21)
MutationEndometrial cancer (12%; ref. 22)
Squamous NSLC (5%; ref. 8)
Gastric cancer (rare; ref. 23)
Germline SNPSecond intron SNP: breast cancer susceptibility (24)
FGFR3AmplificationBladder cancer (25)
Salivary adenoid cystic cancer (26)
MutationBladder cancer (50–60% non-muscle invasive; 10–15% muscle invasive; ref. 27)
Cervical cancer (5%; ref. 28)
Myeloma (5% of the translocated cases; ref. 29)
Prostate cancer (3%; ref. 30)
Spermatocytic seminoma (7%; ref. 31)
Colorectal cancer (23)
Oral squamous cancer (32)
TranslocationMyeloma (15%-20%; ref. 33)
Peripheral T-cell lymphoma (rare; ref. 34)
FGFR4MutationRhabdomyosarcoma (7%-8%; ref. 35)
Germline SNPCoding SNP: poor prognosis in many cancer types (36)